Another example of COVID-19 stock and grants it received.
RidgeBack is collaborating with Merck.
Ridgeback Biotherapeutics is a Miami based biotechnology company, primarily known for their involvement in developing a successful COVID-19 medication.
Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of S.A.C. Capital Advisors[1]) and his wife Wendy Holman.
In early 2020 Ridgeback purchased an exclusive license for the commercial development of Molnupiravir from Emory University, where the drug was initially developed with $16 million in grants from Federal agencies including the National Institutes of Health. The terms of the deal were undisclosed. Molnupiravir was initially researched as a treatment for influenza, but may have broad spectrum activity against other viruses.